ROCKET PHARMACEUTICALS INC (RCKT) Stock Income Statement
NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 270.22M | 273.20M | 256.46M | 221.14M | 167.25M | |||
| Research and Development | 161.96M | 171.24M | 186.34M | 165.57M | 125.48M | |||
| Selling, General, and Administrative Expenses | 108.26M | 101.96M | 70.12M | 55.57M | 41.77M | |||
| Operating Income | -270.22M | -273.20M | -256.46M | -221.14M | -167.25M | |||
| Interest Income/Expense | 4.69M | 6.38M | 3.41M | 2.03M | 90.00K | |||
| Other Income/Expense | 7.50M | 8.08M | 10.65M | 450.00K | -1.91M | |||
| Non Recurring Items | N/A | N/A | -3.20M | -3.20M | N/A | |||
| Income Before Taxes | -258.03M | -258.75M | -245.59M | -221.86M | -169.07M | |||
| Net Income | -258.03M | -258.75M | -245.59M | -221.86M | -169.07M | |||
| EBITDA | -260.11M | -263.83M | -249.36M | -214.87M | -161.88M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.63 | -2.73 | -2.92 | -3.26 | -2.67 | |||
| Non GAAP EPS | -2.63 | -2.73 | -2.94 | -3.29 | -2.68 | |||
| Statistics | ||||||||
All data in USD